AU2006297112B2 - Regulatable fusion promoters - Google Patents

Regulatable fusion promoters Download PDF

Info

Publication number
AU2006297112B2
AU2006297112B2 AU2006297112A AU2006297112A AU2006297112B2 AU 2006297112 B2 AU2006297112 B2 AU 2006297112B2 AU 2006297112 A AU2006297112 A AU 2006297112A AU 2006297112 A AU2006297112 A AU 2006297112A AU 2006297112 B2 AU2006297112 B2 AU 2006297112B2
Authority
AU
Australia
Prior art keywords
promoter
pol
cell
expression
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006297112A
Other languages
English (en)
Other versions
AU2006297112A1 (en
Inventor
Charles Stout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2006297112A1 publication Critical patent/AU2006297112A1/en
Application granted granted Critical
Publication of AU2006297112B2 publication Critical patent/AU2006297112B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2006297112A 2005-10-01 2006-09-29 Regulatable fusion promoters Ceased AU2006297112B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72256805P 2005-10-01 2005-10-01
US60/722,568 2005-10-01
PCT/US2006/038154 WO2007041350A2 (en) 2005-10-01 2006-09-29 Regulatable fusion promoters

Publications (2)

Publication Number Publication Date
AU2006297112A1 AU2006297112A1 (en) 2007-04-12
AU2006297112B2 true AU2006297112B2 (en) 2013-04-18

Family

ID=37906746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006297112A Ceased AU2006297112B2 (en) 2005-10-01 2006-09-29 Regulatable fusion promoters

Country Status (6)

Country Link
US (1) US20090053295A1 (enExample)
EP (2) EP2386564B1 (enExample)
JP (3) JP5976986B2 (enExample)
AU (1) AU2006297112B2 (enExample)
CA (1) CA2665080C (enExample)
WO (1) WO2007041350A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070299029A1 (en) * 2005-06-09 2007-12-27 Agency For Science, Technology And Research Hepatic stellate cell specific promoter and uses thereof
US7863251B2 (en) * 2005-06-09 2011-01-04 Agency For Science, Technology And Research Hepatic stellate cell specific promoter and uses thereof
WO2010033225A2 (en) * 2008-09-22 2010-03-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications
DK2346995T3 (en) * 2008-09-26 2019-02-11 Tocagen Inc GENETERIVE VECTORS AND CYTOSINDEAMINASES
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
KR20110110776A (ko) * 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
EP2909324B1 (en) 2012-10-25 2020-02-26 Tocagen Inc. Retroviral vector with mini-promoter cassette
AU2016317936A1 (en) 2015-09-04 2018-03-08 Tocagen Inc. Recombinant vectors comprising 2A peptide
CN112512573B (zh) * 2018-05-23 2026-02-27 百提威生技股份有限公司 双特异性t细胞衔接蛋白及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050130184A1 (en) * 2003-07-18 2005-06-16 University Of Massachusetts Enhanced promoters for synthesis of small hairpin RNA

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5573933A (en) * 1987-04-14 1996-11-12 Luminis Pty, Ltd. Transgenic pigs
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE190354T1 (de) * 1990-12-20 2000-03-15 Arch Dev Corp The University O Kontrolle der genexpression durch ionisierende strahlung
US5922854A (en) 1991-06-14 1999-07-13 Kumar; Ramesh Purifying Human Hemogloblin from transgenic pig red cells and plasmids containing pig globin nucleic acids
FI945829A7 (fi) 1992-06-12 1995-02-10 Dnx Corp Ihmisen hemoglobiinin valmistaminen transgeenisissa sioissa
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6818209B1 (en) * 1998-05-22 2004-11-16 Oxford Biomedica (Uk) Limited Retroviral delivery system
US6924123B2 (en) * 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
DE19751587A1 (de) * 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme
DE19756975A1 (de) * 1997-12-20 1999-06-24 Hoechst Marion Roussel De Gmbh Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung
JP2002518341A (ja) * 1998-06-15 2002-06-25 アーチ・デヴェロップメント・コーポレイション 放射線療法と抗血管形成因子の組み合わせ
DE19831420A1 (de) * 1998-07-14 2000-01-20 Hoechst Marion Roussel De Gmbh Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren
AU3893000A (en) * 1999-03-16 2000-10-04 Dana-Farber Cancer Institute, Inc. Lentiviral vector system for high quantity screening
WO2000072886A1 (en) * 1999-05-26 2000-12-07 Dana-Farber Cancer Institute, Inc. Episomally replicating lentiviral vectors
JP3704037B2 (ja) * 1999-11-05 2005-10-05 独立行政法人産業技術総合研究所 スライディング可能な機能性キメラ分子
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
JP3613576B2 (ja) * 2000-10-30 2005-01-26 独立行政法人産業技術総合研究所 細胞内で高機能な核酸分子の選択方法
CA2460095A1 (en) * 2001-06-13 2003-12-19 Eastern Virginia Medical School Methods for targeted expression of therapeutic nucleic acid
JP4745563B2 (ja) * 2001-09-11 2011-08-10 一般財団法人 化学物質評価研究機構 レポータープラスミド
GB0130955D0 (en) * 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
US6863884B2 (en) 2002-05-01 2005-03-08 Cell Genesys, Inc. Pseudotyped retroviral vectors
US20050196862A1 (en) * 2002-08-30 2005-09-08 Wooddell Christine I. DNA cassette for cellular expression of small RNA
US6799657B2 (en) 2002-10-02 2004-10-05 Carrier Corporation Absorptive/reactive muffler for variable speed compressors
WO2004056966A2 (en) * 2002-12-18 2004-07-08 Salk Institute For Biological Studies Methods of inhibiting gene expression by rna interference
EP1583832B1 (en) * 2003-01-17 2010-12-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inducible small interfering rna (sirna) expression constructs for targeted gene silencing
US20050013018A1 (en) 2003-07-16 2005-01-20 Alex Ning Compact lens assembly
US20050130919A1 (en) * 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
WO2005021733A2 (en) * 2003-09-02 2005-03-10 The Scripps Research Institute Methods and compositions for sirna expression
US20050166272A1 (en) * 2003-12-09 2005-07-28 National Institute Of Advanced Industrial Science And Technology Enhancement of RNAi activity through mutation
JP4753130B2 (ja) * 2003-12-12 2011-08-24 独立行政法人産業技術総合研究所 インターフェロン応答が軽減された長い干渉用二重鎖ｒｎａ
JPWO2005068630A1 (ja) * 2003-12-16 2007-07-26 独立行政法人産業技術総合研究所 干渉用二重鎖ｒｎａ
US20050164210A1 (en) * 2004-01-23 2005-07-28 Vivek Mittal Regulated polymerase III expression systems and related methods
US20050203047A1 (en) * 2004-03-10 2005-09-15 Ulrich Thomann Delivery vectors for short interfering RNA, micro-RNA and antisense RNA
WO2005112620A2 (en) * 2004-05-18 2005-12-01 Massachusetts Institute Of Technology A cre-lox based method for conditional rna interference
US8008468B2 (en) * 2005-02-16 2011-08-30 Benitec, Inc. RNAi expression constructs with liver-specific enhancer/promoter

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050130184A1 (en) * 2003-07-18 2005-06-16 University Of Massachusetts Enhanced promoters for synthesis of small hairpin RNA

Also Published As

Publication number Publication date
WO2007041350A2 (en) 2007-04-12
EP2386564B1 (en) 2014-07-16
EP1943265A4 (en) 2009-01-14
EP1943265A2 (en) 2008-07-16
CA2665080C (en) 2015-11-24
JP2009509544A (ja) 2009-03-12
JP2016000047A (ja) 2016-01-07
AU2006297112A1 (en) 2007-04-12
EP1943265B1 (en) 2012-09-12
HK1121165A1 (en) 2009-04-17
US20090053295A1 (en) 2009-02-26
JP6199934B2 (ja) 2017-09-20
EP2386564A1 (en) 2011-11-16
WO2007041350A3 (en) 2007-10-04
JP5976986B2 (ja) 2016-08-24
CA2665080A1 (en) 2007-04-12
JP2012254098A (ja) 2012-12-27

Similar Documents

Publication Publication Date Title
JP7601916B2 (ja) 蝸牛および前庭細胞に核酸を送達するための物質および方法
KR102794870B1 (ko) 핵산을 와우 및 전정 세포에 전달하기 위한 물질 및 방법
US20240287452A1 (en) Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
JP2024138266A (ja) 新規Ｃａｓ１２ｂ酵素およびシステム
KR20230091894A (ko) 부위 특이적 표적화 요소를 통한 프로그램 가능한 첨가(paste)를 사용하는 부위 특이적 유전 공학을 위한 시스템, 방법, 및 조성물
US11926839B2 (en) Platform for T lymphocyte genome engineering and in vivo high-throughput screening thereof
AU2021204620A1 (en) Central nervous system targeting polynucleotides
CN109689865A (zh) Bcl11a归巢核酸内切酶变体、组合物和使用方法
KR20190138274A (ko) 클로스트리디움 박테리아의 변형을 위한 최적화된 유전 툴
AU2016228914B2 (en) Tools and methods for using cell division loci to control proliferation of cells
KR20230117177A (ko) 진행성 골화성 섬유이형성증을 위한 신규 유전자 치료제의개발
CN112552380A (zh) 一种SARS-CoV-2病毒的免疫原及其应用
CN101772580A (zh) 专能细胞群的生产和使用方法
KR101921698B1 (ko) 재조합에 의해 제조된 인간 인자 ⅷ 및 ⅸ
CA2665080C (en) Regulatable fusion promoters
CN111094569A (zh) 光控性病毒蛋白质、其基因及包含该基因的病毒载体
CN113423823A (zh) 经基因组编辑的细胞的制造方法
AU2024217163A1 (en) Transposase, transposon, transposon system, and use thereof
CN113614229B (zh) 遗传修饰的梭菌属细菌、其制备和用途
CN114958760B (zh) 一种构建阿尔兹海默症模型猪的基因编辑技术及其应用
CN117795086A (zh) 用于枫糖尿症(msud)中bcaa调节的基因疗法
KR102956722B1 (ko) 박테리아의 변형을 위해 최적화된 유전자 도구
CN112760342B (zh) 一种用于glp-1及其类似物活性测定的慢病毒载体及细胞株
CN108004198B (zh) 基于icam-1信号通路的高通量药物筛选模型的建立方法
CN102154368B (zh) 一种组织特异性兼可调控性慢病毒基因表达载体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired